Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Go back to Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results| (NASDAQ: CMND) | Delayed: 0.78 -0.01 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.79 | 52 Week High | $ | |||
| Open | $0.78 | 52 Week Low | $ | |||
| Day High | $0.79 | P/E | N/A | |||
| Day Low | $0.77 | EPS | $ | |||
| Volume | 76,260 | |||||
